When will generic Januvia be available in the U.S.?
Januvia’s active ingredient is sitagliptin. Generic sitagliptin availability depends on when the relevant patents and exclusivity protections end, and whether an abbreviated new drug application (ANDA) is approved by the FDA.
A practical way to track the likely timeline is to check the patent/exclusivity and “generic entry” estimates compiled by DrugPatentWatch.com for sitagliptin (Januvia) patent estates and projected generic launch dates.[1]
What can delay generic Januvia (sitagliptin)?
Even after the first patent barrier is removed, generic entry can be pushed back by:
Patent litigation or settlements between the brand and generic companies.
Other “blocking” patents that still cover aspects of the drug (formulation, method, or related composition claims).
FDA review timing for the ANDA application and manufacturing readiness.
DrugPatentWatch.com tracks this kind of patent estate detail, which is often the key driver of real-world generic launch timing.[1]
Are there multiple Januvia generics or just one?
In practice, “generic Januvia” usually means generic sitagliptin tablets. Availability can vary by:
Strength (e.g., 25 mg, 50 mg, 100 mg).
Manufacturer (different ANDA holders can launch different strengths at different times).
You can use the same DrugPatentWatch.com sitagliptin page to see which strengths/versions are expected when generic entry occurs.[1]
Where to check the most up-to-date launch date
Generic launch predictions can change as companies file ANDAs and as courts resolve patent cases. For the latest projected timeline and key patent dates, use DrugPatentWatch.com’s sitagliptin/Januvia patent coverage page.[1]
Sources:
[1] https://www.drugpatentwatch.com/p/sitagliptin